YTHDF2 and glioblastoma: In contrast to NSCs, GSCs displayed preferential expression of YTHDF2, laying the foundation for the YTHDF2–MYC–IGF2BP3 axis as a novel therapeutic target in GBM (Dixit et al., 2021).